1927 nm Thulium Laser Hair Growth Study: Growth-Factor Delivery Raises Density 22.7%-25.6% in Randomized Pilot

A newly published randomized clinical study suggests that a 1,927 nm non-ablative fractional thulium laser may do more than stimulate the scalp: it may temporarily open microscopic delivery pathways that help a biomimetic growth-factor serum reach the upper dermis around miniaturising follicles.

Researchers at University Medical Center Hamburg-Eppendorf compared three treatment combinations in adults with androgenetic alopecia. Hair density rose by 25.6% in the thulium-laser, growth-factor-serum and red-light group, by 22.7% with laser-assisted serum delivery alone, and by 4.9% in the energy-device control group, which received laser plus red light without the serum. Hair thickness improved in both serum groups but not in the control group.

Those are intriguing results, but they come from a small pilot study. They do not prove that commercial growth-factor serums are interchangeable, that home devices can reproduce the protocol, or that this approach outperforms minoxidil, finasteride or other established treatments.

What Is It and How Does It Work?

The treatment pairs a 1,927 nm fractionated thulium laser with a topical serum containing biomimetic signalling peptides or growth-factor-like components. The laser wavelength is strongly absorbed by water, allowing it to create an array of controlled, non-ablative microscopic treatment zones while leaving intervening tissue intact.

• Fractional microchannels alter the scalp barrier: The stratum corneum normally blocks large, water-loving molecules from penetrating efficiently. Fractional laser treatment produces microscopic zones through which a professionally manufactured topical formulation may pass more readily.
• Controlled thermal signalling may stimulate repair: Tissue surrounding each microscopic column remains viable and initiates a wound-healing response involving cytokines, extracellular-matrix remodelling and local growth signals.
• The serum reaches a more favourable depth: Applying the formulation immediately after laser treatment may place its signalling molecules closer to follicular epithelial and dermal-papilla compartments than ordinary surface application.
• Red light may add photobiomodulation: Red-light therapy can influence mitochondrial and cellular signalling, but in this study it did not clearly improve the objective hair outcomes beyond laser-assisted serum delivery. Patient satisfaction was higher in the triple-treatment group.

This is not hair cloning and it does not create new follicles. The proposed benefit is improved signalling and cycling in follicles that are still alive but producing progressively thinner fibres.

The Science: What the Randomized Pilot Found

The peer-reviewed study, published online in Lasers in Medical Science on 22 October 2026, was linked to trial registration NCT07079657. The registry listed a target enrolment of 30 adults with androgenetic alopecia at one German academic centre.

Participants were randomly assigned to one of three groups:

• Triple treatment: Non-ablative fractional laser-assisted serum delivery plus red-light therapy.
• Dual treatment: Non-ablative fractional laser-assisted serum delivery without red light.
• Energy-device control: Fractional laser plus red light without the growth-factor serum.

The primary outcomes were objective changes in hair density and hair thickness. Secondary outcomes included satisfaction, tolerability and adverse events.

• Hair density increased 25.6% plus or minus 7.0% in the triple group.
• Hair density increased 22.7% plus or minus 3.4% in the dual group.
• Hair density increased 4.9% plus or minus 9.2% in the energy-device control.
• Hair thickness improved in both groups that received serum, but not in the control group.
• Objective outcomes were similar with and without red light, although satisfaction was higher when red light was included.
• No severe adverse events were reported.

The comparison is valuable because every group received an energy-device intervention. That makes the larger gains in the two serum groups more suggestive of a delivery or formulation effect than a simple before-and-after study. However, the trial was open-label, small and conducted at a single centre. The abstract does not establish long-term durability after treatment stops.

Why the Result Is Biologically Plausible

Hair follicles are deep, complex mini-organs. A conventional cosmetic serum may remain largely on the surface, especially when it contains relatively large signalling molecules. Laser-assisted delivery is designed to bypass part of that barrier for a short period.

Earlier split-scalp research found that 1,927 nm thulium laser monotherapy increased hair density and thickness, with an additional improvement when a growth-factor-containing solution was applied after treatment. A separate 2022 ten-person pilot also reported increased density and diameter after fractional thulium laser followed by a proprietary serum. The new randomized comparison adds a stronger control group, but it still does not identify which individual serum components matter most.

The mechanism may involve two cooperating effects: controlled fractional injury may activate a repair environment, while assisted delivery exposes follicular cells to a concentrated signalling mixture. Whether the dominant factor is enhanced penetration, laser-induced repair, a specific peptide, or their combination remains uncertain.

What Is Proven, Plausible and Still Unknown?

• Shown in this pilot: Both laser-assisted serum groups had substantially larger percentage increases in hair density than the energy-device control, and both improved hair thickness.
• Biologically supported: Fractional thulium lasers create non-ablative microscopic treatment zones and can increase transdermal delivery.
• Plausible: Improved access to follicular compartments plus wound-repair signalling may help viable miniaturising follicles produce thicker fibres.
• Not established: Superiority to minoxidil, finasteride, dutasteride, platelet-rich plasma or transplantation; durability beyond follow-up; optimal maintenance frequency; and cost-effectiveness.
• Product-specific uncertainty: The result cannot be generalized to every serum marketed as containing growth factors, peptides, exosomes or stem-cell conditioned media.

When Will It Be Available?

Fractional thulium lasers are already used in dermatology and aesthetic clinics, and some clinics already combine them with topical hair serums. That does not mean there is a standardized, regulator-approved hair-loss protocol. Laser parameters, treatment intervals, formulation quality, sterility and clinician experience can vary widely.

The published study supports further clinical evaluation rather than immediate self-treatment. Larger multicentre trials should compare the protocol with sham treatment and established therapy, track outcomes for at least 12 months and publish the exact formulation and dosing schedule.

How You Can Benefit from This Research Now

• Confirm that follicles remain viable: A dermatologist can distinguish miniaturising follicles from scarring alopecia, where laser-assisted cosmetic treatment may be inappropriate.
• Ask for the exact device and protocol: Confirm the wavelength, fractional settings, treatment frequency, number of sessions and who operates the medical laser.
• Demand formulation transparency: Ask for the complete ingredient list, manufacturer, sterility information and evidence for that exact serum. A generic “growth factor” label is not enough.
• Do not use research-grade proteins or inject cosmetic serum: The trial used controlled clinical delivery. Unregulated proteins, exosome products and home microneedling combinations can introduce infection, allergy and contamination risks.
• Keep established therapy stable: If a clinician adds laser-assisted delivery, changing minoxidil or antiandrogen treatment at the same time makes it impossible to know what produced the result.
• Track objectively: Take standardized photographs and request trichoscopic density and shaft-diameter measurements at baseline and follow-up.

Action: Before paying for a laser-and-growth-factor package, ask the clinic to show evidence for the exact serum and device settings it uses, explain who is medically responsible for complications, and provide a plan for measuring density rather than relying only on photographs.

Sources

• Nguyen L, Schneider SW, Herberger K. Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia: a randomized, controlled, clinical study. Lasers Med Sci. 2026.
• ClinicalTrials.gov registration NCT07079657.
• Earlier evaluator-blinded split-scalp study of 1,927 nm thulium laser with growth-factor solution.
• 2022 fractional thulium laser and growth-factor serum pilot.